Company formed to create first oral integrin therapies for wide range of diseases, leveraging new discoveries from the lab of Scientific Founder Tim Springer, Ph.D.
This question was submitted during the Morphic Therapeutic HiPO class Nov 2017.
As a chemist coming out of graduate school, what are the type of experiences that I should be looking for in my 1st few years in industry?
As a chemist coming out of grad school, you want to learn about medicinal chemistry. There are a few good courses one could take that will give you the basics. The Residential School on Medicinal Chemistry and Biology in Drug Discovery at Drew University and the Medicinal Chemistry Gordon Research Seminar are two of them. As good as these courses can be, they are not going to replace the experience you are going to get from working within your company …
Here’s to the fact that all great things start the same.
Despite all of Tim Springer’s achievements – tributes, awards, companies, and other accomplishments – his latest philanthropic venture launches grand in vision but step-by-step and local in action.
Integration between biotech and Big Pharma has never before looked like this.
Both Astra Zeneca and Morphic Therapeutic decided to forego an originally planned divider wall. As far as we know, this creates the 1st completely integrated labs between Big Pharma and Biotech leading to valued personal interaction; and sharing of ideas, equipment, and resources.
A Pot of Gold.
I was looking into Novel Targets at Merck about a year ago, specifically for diabetic retinopathy. I became very excited about integrins as potential targets for diabetic retinopathy and age-related macular degeneration.
In this video, CEO Praveen Tpirneni explains what he found most surprising in Series A fundraising for Morphic Therapeutic.
Over the last 20 years there has been major innovation in treatment of Inflammatory Bowel Disease (IBD) catalyzed due the biologics that offer greater on target selectivity than aminosalicylates, corticosteroids or immunosupressants.
In today’s capital efficient environment, why would Morphic decide to bring crystallography capabilities in-house?